

Apol	lo	Hos	nita	ls
<b>Aho</b> i		103	μιια	13

Estimate change	$\longleftrightarrow$
TP change	
Rating change	

Bloomberg	APHS IN
Equity Shares (m)	144
M.Cap.(INRb)/(USDb)	989.3 / 11.6
52-Week Range (INR)	7545 / 5691
1, 6, 12 Rel. Per (%)	-3/-2/9
12M Avg Val (INR M)	2634

#### Financials & Valuations (INR b)

	FY26E	FY27E
217.9	246.5	290.0
30.2	34.8	41.8
14.5	17.4	22.0
13.9	14.1	14.4
100.6	121.0	153.2
61.1	20.3	26.6
590.3	709.3	861.6
0.2	-0.1	-0.2
19.1	19.2	20.2
15.3	14.8	16.4
5.8	4.8	3.8
68.5	56.9	45.0
34.1	29.0	23.6
0.1	0.1	0.1
0.4	2.4	2.8
4.7	4.1	3.4
	30.2 14.5 13.9 100.6 61.1 590.3 0.2 19.1 15.3 5.8 68.5 34.1 0.1 0.4	30.2       34.8         14.5       17.4         13.9       14.1         100.6       121.0         61.1       20.3         590.3       709.3         0.2       -0.1         19.1       19.2         15.3       14.8         5.8       4.8         68.5       56.9         34.1       29.0         0.1       0.1         0.4       2.4

#### Shareholding Pattern (%)

As On	Mar-25	Dec-24	Mar-24				
Promoter	29.3	29.3	29.3				
DII	22.5	20.2	19.8				
FII	42.7	45.3	45.6				
Others	5.4	5.2	5.3				
FII includes depository receipts							

#### CMP: INR6,880

TP: INR8,050 (+17%)

Buy

### Operationally in-line 4Q; ends FY25 on a strong note

#### Beds addition/improving GMV to drive overall better outlook

- Apollo Hospitals Enterprises (APHS) posted marginally better-than-expected revenue (4% beat), while EBITDA was in line for the quarter. The lower tax rate led to better-than-expected earnings for the quarter.
- While operating beds inched up for FY25, APHS delivered healthy revenue growth in healthcare services (10%/13% YoY for 4QFY25/FY25), driven by improved case mix and occupancy. Further, the addition of beds is on track (870 beds in FY26; 10% YoY increase).
- The cash loss in the digital segment of Healthco has reduced from INR1.1b in 4QFY24 to INR798m in 4QFY25 and is expected to break even in 2Q/3QFY26.
- Primary care within the AHLL segment saw a sharp improvement in margins QoQ led by superior execution, while diagnostics witnessed a moderation in margins due to the ongoing strategic reset in the business.
- We broadly retain our estimates for FY26/FY27. We value APHS on an SoTP basis (30x EV/EBITDA for the hospital business, 15x EV/EBITDA for retained pharmacy, 23x EV/EBITDA for AHLL, 22x EV/EBITDA for front-end pharmacy, and 2x EV/sales for Apollo 24/7) to arrive at our TP of INR8,050.
- We expect a 15%/17%/23% CAGR in revenue/EBITDA/PAT over FY25-27. This would mainly be driven by 1) the addition of beds in the healthcare services segment coupled with improvement in productivity at existing facilities, 2) reduction in losses at the healthco level, and 3) revival in revenue growth/profitability in the diagnostic segment. **Reiterate BUY.**

#### Strong growth across segments; EBITDA margin inches up to 13.8% in 4Q

- APHS' 4QFY25 revenue grew 13.1% YoY to INR55.9b (est. INR53.7b).
- Healthcare services (hospitals) revenue grew 10.3% YoY to INR28.2b. The Healthco revenue grew 17.2% YoY to INR23.7b. AHLL revenue grew 11.1% YoY to INR3.9b.
- EBITDA margin expanded 80bp YoY to 13.8% (our est. of 14.3%) due to lower other expenses (160bp YoY as % sales) offset by an increase in RM costs (80bp YoY as % sales).
- EBITDA grew 20.2% YoY to INR7.6b (in line with estimates).
- Adj. PAT grew 53.5% YoY to INR3.9b (our est: INR3.5b).
- Its revenue/EBITDA/PAT grew 14.3%/26.4%/61% to INR217b/INR30.2b/ INR14.2b in FY25.
- Healthcare services EBITDA grew 16% YoY to INR6.8b for 4QFY25. EBITDA margin grew 20bp YoY to 24.3% in 4QFY25. Healthco exhibited EBITDA of INR363m for 4QFY25 vs. INR566m for 3QFY25. AHLL's EBITDA grew 32% YoY in 4QFY25 to INR472m (EBITDA margin at 12%).
- GMV for Apollo 24/7 grew 11% YoY to INR8b in 4QFY25.
- Max added 266 offline pharmacy stores in 4Q, bringing the total to 6,626.

#### Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.



#### Highlights from the management commentary

- APHS is on track to achieve cash EBITDA breakeven (excluding ESOP cost) in Healthco by 2QFY26/3QFY26.
- Management sees GMV growth of 25-30% YoY in FY26.
- APHS indicated the sales: GMV ratio to be 40-45% in FY26 (37% in FY25).
- The company expects to maintain profitability of the healthcare services segment despite the new addition of operating beds, led by increased occupancy at existing facilities and cost optimization.
- It expects healthcare services revenue to grow by low teens organically. There is potential to add INR10b in revenue from inorganic initiatives in FY27.

Y/E March	_	FY2	4			FY2	25		FY24	FY25E	FY25E	vs Est
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Gross Sales	44,178	48,469	48,506	49,439	<b>50,856</b>	55 <i>,</i> 893	55 <i>,</i> 269	55,922	1,90,592	2,17,940	53,753	4.0%
YoY Change (%)	16.4	14.0	13.8	14.9	15.1	15.3	13.9	13.1	14.7	14.3	8.7	
Total Expenditure	39,088	42,194	42,369	43,034	44,105	47,738	47,654	48,225	1,66,685	1,87,722	46,064	
EBITDA	5,090	6,275	6,137	6,405	6,751	8,155	7,615	7,697	23,907	30,218	7,689	0.1%
YoY Change (%)	3.7	11.0	21.4	31.2	32.6	30.0	24.1	20.2	16.6	26.4	20.0	
Margins (%)	11.5	12.9	12.7	13.0	13.3	14.6	13.8	13.8	12.5	13.9	14.3	
Depreciation	1,669	1,634	1,670	1,897	1,774	1,845	1,846	2,110	6,870	7,575	1,866	
Interest	1,062	1,113	1,126	1,193	1,164	1,175	1,098	1,148	4,494	4,585	1,118	
Other Income	282	222	278	281	372	382	638	611	1,063	2,003	442	
PBT before EO expense	2,641	3,750	3,619	3,596	4,185	5,517	5,309	5,050	13,606	20,061	5,147	-1.9%
Extra-Ord expense/(Income)	0	-19	0	0	0	0	0	0	-19	0	0	
РВТ	2,641	3,769	3,619	3,596	4,185	5,517	5,309	5,050	13,625	20,061	5,147	-1.9%
Тах	966	1,300	1,089	1,098	1,145	1,617	1,568	1,010	4,455	5,340	1,556	
Rate (%)	36.6	34.5	30.1	30.5	27.4	29.3	29.5	20.0	32.7	26.6	30.2	
MI & Profit/Loss of Asso. Cos.	9	140	77	-40	-12	112	18	144	186	262	75	
Reported PAT	1,666	2,329	2,453	2,538	3,052	3,788	3,723	3,896	8,984	14,459	3,516	10.8%
Adj PAT	1,666	2,317	2,453	2,538	3,052	3,788	3,723	3,896	8,973	14,459	3,516	10.8%
YoY Change (%)	2.6	3.0	59.8	47.1	83.2	63.5	51.8	53.5	29.6	61.1	38.5	
Margins (%)	3.8	4.8	5.1	5.1	6.0	6.8	6.7	7.0	4.7	6.5	6.5	
EPS	11.6	16.1	17.1	17.7	21.2	26.3	25.9	27.1	62.4	100.6	24.5	

#### **Consolidated - Quarterly Earnings Model**

E: MOFSL Estimates

#### **Key performance Indicators (Consolidated)**

Y/E March		FY	24		FY25E				FY24	FY25E	FY2	5E
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	vs Est
Hospital Revenue (INRm)	22,937	25,472	24,636	25,591	26,373	29,032	27,850	28,220	98,636	1,11,475	27,739	1.7%
YoY Growth (%)	13.4	12.5	12.3	16.6	15.0	14.0	13.0	10.3	13.7	13.0	8.4	
Healthco (INRm)	18,054	19,454	20,493	20,267	20,821	22,822	23,524	23,763	78,269	90,930	22,205	7.0%
YoY Growth (%)	22.1	16.6	16.6	12.6	15.3	17.3	14.8	17.2	16.7	16.2	9.6	
AHLL Revenue (INRm)	3,187	3,542	3,377	3,547	3,661	4,039	3,895	3,940	13,653	15,535	3,809	3.4%
YoY Growth (%)	8.8	11.3	8.4	15.0	14.9	14.0	15.3	11.1	10.9	13.8	7.4	
Cost Break-up												
Gross Margin (%)	48.7	49.3	47.8	48.5	48.4	48.9	47.5	47.6	48.6	48.1	49.6	
EBITDA Margin (%)	11.5	12.9	12.7	13.0	13.3	14.6	13.8	13.8	12.5	13.9	14.3	
PAT Margin (%)	3.8	4.8	5.1	5.1	6.0	6.8	6.7	7.0	4.7	6.6	6.5	





# Highlights from the management commentary

- Apollo 24/7 does not have any plan to tie up with such quick commerce companies. APHS has already rolled out 19-min delivery in select cities and intends to further expand the service to more cities.
- New business segments like insurance in Apollo 24/7 (started on Apr'25) expect to have a revenue run-rate of INR60-INR70m quarterly over the near term.
- INR8b GMV for the quarter has 80% from Rx medicines and 20% from health essentials/FMCG products.
- APHS would have hospitals at Pune, Kolkata, and Sarjapur commencing operations from 2HFY26
- The volume of patients treated was impacted due to geo-political issues at Bangladesh for the quarter. Expect the patients-inflow from Bangladesh to revive in the near term.
- APHS has a target to add 600 stores every year on the offline pharmacy side
- The diagnostic business has witnessed a slowdown due to the reset of its franchise business. The revenue growth is expected to revive soon
- Healthy volume growth in primary care is driving better profitability in this segment for 4QFY25.

### Other operational highlights

#### Hospitals segment (50% of sales)

- Hospital EBITDA grew 16% YoY to INR6.8b for 4QFY25. EBITDA margin grew 20bp YoY at 24.3% in 4QFY25.
- ARPOB grew by 7% YoY to INR 63,569 in 4QFY25. Effectively, the volume of patients treated grew ~4% YoY for 4QFY25.
- Occupancy for 4QFY25 is 67% vs 68% in 3QFY25.
- ALOS in 4QFY25 stood flat at 3.3 days.

### Healthco (offline/online pharmacy and Apollo 24/7; 43% of sales)

- Healthco exhibited EBITDA of INR363m for 4QFY25 vs INR566m in 3QFY25.
- Platform GMV grew 11% YoY to INR7.9b. It is stable QoQ. Platform GMV grew 8% YoY to INR30b in FY25.
- A total of 6,626 operating stores as of 31<sup>st</sup> Mar'25. 596 stores were added in FY25.


### AHLL (7% of sales)

- Revenue/EBITDA grew by 11.1%/32% YoY in 4QFY25 to INR3.9b/INR472m
- Revenue of primary care grew 12% YoY in 4QFY25 to INR1.1b
- Revenue of specialty care grew 9.6% YoY in 4QFY25 to INR1.7b
- Network collection centers reduced by 155 centers YoY to reach 2,108 centers.




### **Key exhibits**


#### Exhibit 1: Revenue for hospitals grew 10.1% YoY in 4QFY25



#### Exhibit 2: Hospitals' EBITDA margin expanded 120bp YoY




#### Exhibit 4: AHLL – EBITDA margin expanded 170bp YoY




Source: MOFSL, Company

#### Exhibit 6: APHS – overall EBITDA margin up 80bp YoY




Source: MOFSL, Company

#### Exhibit 3: AHLL – revenue grew 11.1% YoY in 4QFY25



Source: MOFSL, Company

#### Exhibit 5: APHS – overall revenue grew 13% YoY in 4QFY25



Source: MOFSL, Company



#### Exhibit 7: ARPOB grew 7% YoY in 4QFY25



Source: MOFSL, Company

Exhibit 8: Occupancy increased 200bp YoY in 4QFY25

Occupancy (in %)

66

3QFY24

65

4QFY24

68

1QFY25

73

2QFY25


68

**3QFY25** 

Source: MOFSL, Company

67

4QFY25



Source: MOFSL, Company

#### Source: MOFSL, Company

# Expanding pan-India reach in all segments to drive growth

65

**3QFY23** 

68

2QFY23

64

**24FY23** 

62

IQFY24

68

2QFY24

# Hospitals: improved profitability/occupancy at existing sites and bed additions to drive overall growth

- In FY25, the hospital segment's revenue grew 13% YoY to INR111b. This growth was led by ~300bp YoY growth in occupancy to 69%, coupled with 7% YoY growth in IP volumes and 5% YoY growth in ARPP to INR163k.
- ARPOB rose 5% YoY to INR60.5k, driven by a higher share of CONGO therapies and higher realization per patient.
- CONGO Cardiac, Onco, Neuro, Nephro, Gastro, and Ortho contributed ~62% to the total IP revenue.
- Additionally, over the next 3-4 years, AHEL has plans to add 3.577 beds for a total capex outlay of INR81b (of which INR20b has already been incurred).
- We expect a 15% sales CAGR in the hospitals segment, reaching INR147b over FY25-27.

# Apollo Healthco: Strong GMV growth, store addition to drive healthy outlook

- During FY25, offline pharmacy revenue grew 16% YoY to INR80b. Moreover, online pharmacy revenue jumped 20% YoY to INR10.7b.
- AHEL added 596 stores in FY25, bringing the total count to 6,626.
- Interestingly, the GMV of 24/7 increased 8% YoY to INR30b in FY25.




 With new levers of growing GMV, stores addition and continuous cost optimization, we expect an 18% sales CAGR in the healthco, reaching INR123.5b over FY25-27.

# AHLL: Primary/secondary clinics on sustainable growth path; diagnostics to revive soon

- In FY25, AHLL sales grew 14% YoY to INR13.6b, primarily attributed to the maturing network. The primary care revenue grew 14% YoY to INR3.7b, specialty care grew 15% YoY to INR7b. The diagnostic business grew moderately at 9% YoY to INR5b.
- The margin profile of primary/specialty care improved 150bp/60bp in FY25, while diagnostic segment EBITDA margin dipped 40bp YoY to 10.5% in FY25.
- The overall footfalls per day increased 11% YoY in FY25 to 23,049.
- Considering the business re-set in diagnostic and sustained growth momentum in primary/secondary clinics, we project a CAGR of 12% in sales in this segment over FY25-27.

#### **Reiterate BUY**

- We broadly retain our estimates for FY26/FY27. We value APHS on an SOTP basis (30x EV/EBITDA for the hospital business, 15x EV/EBITDA for retained pharmacy, 23x EV/EBITDA for AHLL, 22x EV/EBITDA for front-end pharmacy, and 2x EV/sales for Apollo 24/7) to arrive at our TP of INR8,050.
- We expect a 15%/17%/23% CAGR in revenue/EBITDA/PAT over FY25-27. This would mainly be driven by 1) the addition of beds in the healthcare services segment coupled with improvement in productivity at existing facilities, 2) reduction in losses at the healthco level, and 3) revival in revenue growth/profitability in the diagnostic segment. Reiterate BUY.




Source: MOFSL, Company, Bloomberg

Source: MOFSL, Company, Bloomberg




# Story in charts

# Exhibit 13: Expect a 15% sales CAGR over FY25-27 in the hospitals segment



# Exhibit 14: Expect a 12% sales CAGR over FY25-27 in the AHLL segment



12.3 12.5

Source: Company, MOFSL

14.1


Source: Company, MOFSL

13.9

14.4

Ο

#### Exhibit 15: Expect 14% overall revenue CAGR during FY25-27 Revenue (INRb) -O-YoY Growth (%) -O-EBITDA Margin(%)



Source: Company, MOFSL






Exhibit 18: Expect RoE to improve over FY25-27

14.9


14.1

 $\mathbf{\cap}$ 

10.8

11.1

O



FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26E FY27E



# **Financials and valuation**

Consolidated - Income Statement	51/20	5/24	51/22	51/22	51/2.4	51/25	EVACE	(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Total Income from Operations	1,12,468	1,05,600	1,46,626	1,66,124	1,90,592	2,17,940	2,46,476	2,89,959
Change (%)	16.9	-6.1	38.9	13.3	14.7	14.3	13.1	17.6
Total Expenditure	96,596	94,226	1,24,775	1,45,628	1,66,685	1,87,722	2,11,723	2,48,205
% of Sales	85.9	89.2	85.1	87.7	87.5	86.1	85.9	85.6
EBITDA	15,872	11,374	21,851	20,496	23,907	30,218	34,753	41,754
Margin (%)	14.1	10.8	14.9	12.3	12.5	13.9	14.1	14.4
Depreciation	6,197	5,731	6,007	6,152	6,870	7,575	7,834	8,118
EBIT	9,675	5,643	15,844	14,343	17,037	22,643	26,919	33,636
Int. and Finance Charges	5,328	4,492	3,786	3,808	4,494	4,585	4,466	4,172
Other Income	270	450	781	903	1,063	2,003	2,265	1,740
PBT bef. EO Exp.	4,617	1,601	12,839	11,439	13,606	20,061	24,718	31,203
EO Items	1,952	614	2,941	0	19	0	0	0
PBT after EO Exp.	6,569	2,215	15,781	11,439	13,625	20,061	24,718	31,203
Total Tax	2,252	847	4,770	2,562	4,455	5,340	7,045	8,893
Tax Rate (%)	34.3	38.2	30.2	22.4	32.7	26.6	28.5	28.5
Minority Interest	-231	-8	454	687	184	262	275	289
Reported PAT	4,548	1,368	10,557	8,190	8,986	14,459	17,398	22,021
Adjusted PAT	3,265	870	9,787	6,923	8,973	14,459	17,398	22,021
Change (%)	38.3	-73.4	1,024.9	-29.3	29.6	61.1	20.3	26.6
Margin (%)	2.9	0.8	6.7	4.2	4.7	6.6	7.1	7.6
Consolidated - Balance Sheet								(INRm)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	696	719	719	719	719	719	719	719
Total Reserves	32,695	45,306	55,733	61,253	68,635	81,404	97,961	1,19,141
Net Worth	33,390	46,025	56,452	61,971	69,354	82,123	98,680	1,19,860
Minority Interest	1,307	1,999	2,543	3,341	3,851	4,406	4,406	4,406
Total Loans	38,567	30,846	26,357	27,103	31,619	52,752	47,852	42,952
Non-Current Lease Liabilities	18,676	12,301	13,333	14,983	19,814	24,139	24,139	24,139
Deferred Tax Liabilities	2,447	2,354	5,215	4,303	4,389	4,449	4,449	4,449
Capital Employed	94,387	93,525	1,03,900	1,11,702	1,29,027	1,67,869	1,79,526	1,95,806
Gross Block	98,760	92,371	1,07,815	1,15,853	1,34,187	1,56,048	1,63,716	1,67,650
Less: Accum. Deprn.	27,960	28,395	34,402	40,554	47,424	54,999	62,834	70,952
Net Fixed Assets	70,800	63,976	73,413	75,298	86,763	1,01,049	1,00,883	96,698
Goodwill on Consolidation	3,462	3,753	9,235	9,858	10,123	10,305	10,305	10,305
Capital WIP	2,356	2,339	455	6,098	8,447	7,710	3,042	2,108
Total Investments	4,631	13,659	8,063	5,777	9,895	24,896	24,896	24,896
Curr. Assets, Loans&Adv.	31,639	30,188	40,893	47,125	52,194	62,483	83,956	1,12,935
Inventory	7,378	2,495	4,318	3,902	4,598	4,808	5,423	6,357
Account Receivables	10,272	13,311	17,676	22,342	25,149	30,161	34,110	40,128
Cash and Bank Balance	4,668	7,244	10,359	7,758	9,338	13,602	28,689	47,940
Loans and Advances	9,321	7,138	8,541	13,123	13,109	13,912	15,734	18,509
Curr. Liability & Prov.	18,501	20,390	28,159	32,454	38,395	38,574	43,556	51,136
Account Payables	9,898	12,328	16,318	19,157	23,686	22,405	25,270	29,624
Other Current Liabilities	7,271	6,746	10,420	11,597	12,543	13,490	15,256	17,948
		1,316	1,421	1,701	2,166	2,679	3,030	3,564
Provisions	1.55	1.310		1.707				
Provisions Net Current Assets	1,331 <b>13,138</b>	9,798	12,734	14,671	13,799	<b>23,909</b>	<b>40,400</b>	61,799



## **Financials and valuation**

Ratios								
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Basic (INR)								
EPS	22.7	6.1	68.1	48.2	62.4	100.6	121.0	153.2
Cash EPS	68.0	47.4	113.5	94.0	113.9	158.4	181.4	216.6
BV/Share	240.0	330.8	405.8	445.5	498.5	590.3	709.3	861.6
DPS	6.7	3.0	5.0	5.0	5.0	5.0	5.0	5.0
Payout (%)	22.4	31.5	8.0	10.3	9.4	5.8	4.8	3.8
Valuation (x)								
P/E	303.2	1,137.9	101.2	143.0	110.3	68.5	56.9	45.0
Cash P/E	101.2	145.1	60.7	73.3	60.5	43.5	38.0	31.8
P/BV	28.7	20.8	17.0	15.5	13.8	11.7	9.7	8.0
EV/Sales	8.8	9.6	6.9	6.1	5.3	4.7	4.1	3.4
EV/EBITDA	62.5	89.1	46.0	49.3	42.3	34.1	29.0	23.6
Dividend Yield (%)	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
FCF per share	56.2	69.1	67.0	17.3	54.6	30.5	162.1	192.8
Return Ratios (%)								
RoE	9.8	2.2	19.1	11.7	13.7	19.1	19.2	20.2
RoCE	8.9	5.1	14.5	13.8	12.8	15.3	14.8	16.4
RoIC	8.7	4.6	14.2	12.6	11.9	14.9	15.7	19.7
Working Capital Ratios								
Inventory (Days)	24	9	11	9	9	8	8	8
Debtor (Days)	33	46	44	49	48	51	51	51
Creditor (Days)	32	43	41	42	45	38	37	37
Leverage Ratio (x)								
Current Ratio	1.7	1.5	1.5	1.5	1.4	1.6	1.9	2.2
Interest Cover Ratio	1.8	1.3	4.2	3.8	3.8	4.9	6.0	8.1
Net Debt/Equity	0.9	0.2	0.1	0.2	0.2	0.2	-0.1	-0.2
ii								
Consolidated - Cash Flow Statement								(INR m)
Y/E March	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
OP/(Loss) before Tax	4,317	1,368	11,084	8,446	9,350	15,051	24,718	31,203
Depreciation	6,197	5,731	6,007	6,152	6,870	7,575	7,834	8,118
Interest & Finance Charges	5,155	4,274	3,786	3,808	8,949	9,848	2,201	2,433
Direct Taxes Paid	-3,061	353	-2,043	-3,820	-4,667	-4,860	-7,045	-8,893
(Inc)/Dec in WC	-703	-721	-4,630	-4,500	-1,928	-6,039	-1,404	-2,148
CF from Operations	11,905	11,005	14,204	10,087	18,574	21,575	26,305	30,714
Others	1,024	1,729	1,953	3,684	628	-211	0	0
CF from Operating incl EO	12,929	12,734	16,156	13,771	19, <b>202</b>	21,364	26,305	30,714
(Inc)/Dec in FA	-5,106	-2,804	-6,518	-11,285	-11,349	-16,978	-3,000	-3,000
Free Cash Flow	7,823	9,9 <b>30</b>	9,639	2,485	7,853	4,386	23,305	27,714
(Pur)/Sale of Investments	2,043	-6,207	-1,859	2,065	-4,416	-17,770	0	0
Others	175	288	469	515	393	942	2,265	1,740
CF from Investments	-2,888	-8,723	-7,907	-8,706	-15,372	-33,806	-735	-1,260
Issue of Shares	0	11,520	0	45	25	459	0	0
Inc/(Dec) in Debt	-571	-8,985	-2,866	688	2,246	18,525	-4,900	-4,900
Interest Paid	-5,645	-4,676	-3,764	-2,514	-3,029	-3,018	-4,466	-4,172
Dividend Paid	-1,551	-383	-433	-2,579	-2,209	-2,784	-841	-841
CF from Fin. Activity	-9,095	-3,567	-7,677	-5,582	-3,081	13,168	-10,483	-10,202
Inc/Dec of Cash	946	444	572	-518	749	726	15,087	19,251
	2.002	2.000	4 252	4 02 4	4 200	F 0FF	F 701	20.000

4,252

4,824

5,535

10,359

4,824

4,306

3,452

7,758

4,306

5,055

4,283

9,338

5,055

5,781

7,821

13,602

3,808

4,252

2,992

7,244

2,862

3,808

4,668

860

**Opening Balance** 

**Closing Balance** 

**Total Cash and Cash Equivalent** 

Bank Balance

20,868

40,119

7,821

47,940

5,781

20,868

7,821

28,689



NOTES

### motilal OSWal

Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	< - 10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						
*In case the recommendation given by the	Pesearch Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Pesearch Analyst shall be within t						

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/Ldocuments/List%200f%20Associate%20Companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views. Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions. For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motifal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and will be engaged in therpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL . In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Nainesn Rajani

Email: nainesh.rajani@motilaloswal.com Contact: (+65) 8328 0276

Specific Disclosures

 Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes. Nature of Financial interest is holding equity shares or derivatives of the subject company

Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately
preceding the date of publication of Research Report.

MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No

- 3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- 4. Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- 5. Research Analyst has not served as an officer, director or employee of subject company(ies).



- 6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months. 7.
- 8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report. q
- 10

MOFSL may have received compensation of ourse octions and the subject company. MOFSL has not engaged in market making activity for the subject company.

#### The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report. Disclaimer

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

#### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MOX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.